



RESEARCH REPORT



Molecular Diagnostics for Infectious Disease

By Syndrome, Plex, Place and by Country.

With Analysis and Executive Guides.

2024 – 2028



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

- 1 Market Guides28
 - 1.1 Strategic Situation Analysis..... 29
 - 1.2 Guide for Executives and Business Development Staff..... 31
 - 1.3 Guide for Management Consultants and Investment Advisors..... 32
- 2 Introduction and Market Definition33
 - 2.1 What are Molecular Diagnostics? 34
 - 2.2 The Diagnostics Revolution..... 35
 - 2.3 Market Definition 37
 - 2.3.1 Revenues..... 37
 - 2.4 Methodology..... 39
 - 2.4.1 Methodology 39
 - 2.4.2 Sources 39
 - 2.4.3 Authors 39
 - 2.5 Perspective: Healthcare and the IVD Industry 41
 - 2.5.1 Global Healthcare Spending 41
 - 2.5.2 Spending on Diagnostics 42
 - 2.5.3 Important Role of Insurance for Diagnostics 44
- 3 The Infectious Diseases – Market Analysis by Disease45
 - 3.1 HIV - Human Immunodeficiency Virus (AIDS) 46
 - 3.1.1 Virology 46

3.1.1.1	Classification	46
3.1.1.2	Structure and genome.....	47
3.1.1.3	Tropism.....	50
3.1.1.4	Replication cycle.....	52
3.1.1.5	Genetic variability	58
3.1.2	Diagnosis	59
3.1.3	Testing.....	61
3.1.3.1	Antibody tests	61
3.1.3.2	Point of Care Tests (POCT)	64
3.1.3.3	Antigen Tests	67
3.1.3.4	Nucleic acid-based tests (NAT)	67
3.1.3.5	Other tests used in HIV treatment.....	68
3.1.4	Market Opportunity Analysis	69
3.2	HBV – Hepatitis B.....	74
3.2.1	Virology	75
3.2.1.1	Genome	76
3.2.1.2	Pathogenesis.....	77
3.2.1.3	Hepatitis B virus replication	77
3.2.1.4	Serotypes and genotypes.....	78
3.2.2	Mechanisms.....	78
3.2.3	Diagnosis	79
3.2.4	Market Opportunity Analysis	80
3.3	HCV – Hepatitis C.....	82
3.3.1	Taxonomy.....	83

3.3.2	Structure	84
3.3.2.1	Genome	84
3.3.3	Molecular biology	85
3.3.4	Replication.....	87
3.3.5	Genotypes	88
3.3.5.1	Clinical importance.....	89
3.3.6	Market Opportunity Analysis	89
3.4	HPV - Human papillomavirus.....	91
3.4.1	Virology	93
3.4.1.1	E6/E7 proteins.....	93
3.4.1.2	Role in cancer.....	93
3.4.1.3	E2 research.....	94
3.4.1.4	Latency period	96
3.4.1.5	Clearance	96
3.4.2	Diagnosis	96
3.4.2.1	Cervical testing.....	96
3.4.2.2	Oral testing	98
3.4.2.3	Testing men	98
3.4.2.4	Other testing	100
3.4.3	Market Opportunity Analysis	100
3.5	Influenza.....	106
3.5.1	Virology	108
3.5.1.1	Types of virus	108
3.5.1.2	Influenzavirus A	108

3.5.1.3	Influenzavirus B.....	109
3.5.1.4	Influenzavirus C.....	109
3.5.1.5	Structure, properties, and subtype nomenclature.....	109
3.5.1.6	Replication.....	111
3.5.2	Testing.....	113
3.5.2.1	Advantages/Disadvantages of Molecular Assays.....	115
3.5.3	Market Opportunity Analysis.....	116
3.6	CTGC - Chlamydia/Gonorhea.....	126
3.6.1	Gonorrhea.....	126
3.6.1.1	Diagnosis.....	127
3.6.1.2	Screening.....	127
3.6.2	Chlamydia.....	127
3.6.2.1	Diagnosis.....	128
3.6.2.2	Screening.....	129
3.6.3	Testing.....	130
3.6.3.1	Nucleic acid amplification tests (NAATs).....	130
3.6.3.2	Performance of NAAT Tests.....	139
3.6.4	Market Opportunity Analysis.....	140
3.7	Tuberculosis.....	142
3.7.1	Mycobacteria.....	143
3.7.2	Diagnosis.....	145
3.7.2.1	Active tuberculosis.....	145
3.7.2.2	Latent tuberculosis.....	145
3.7.3	Epidemiology.....	146

3.7.4	Molecular Diagnostic Tests	148
3.7.5	Market Opportunity Analysis	149
3.8	MRSA - Methicillin-resistant Staphylococcus aureus	151
3.8.1	Diagnosis	151
3.8.2	FDA Approved Molecular Tests	152
3.8.3	Market Opportunity Analysis	153
3.9	VRE - Vancomycin-resistant Enterococcus.....	155
3.9.1	FDA Approved MDx Tests for VRE.....	156
3.9.2	Market Opportunity Analysis	157
3.10	Blood Screening	158
3.10.1	Collection and Testing	158
3.10.2	FDA Approved Multiplex Assays.....	159
3.10.3	Market Opportunity Analysis	161
3.11	COVID-19	162
3.11.1	Signs and symptoms.....	163
3.11.2	Transmission.....	165
3.11.3	Diagnosis	166
3.11.4	Prevention	168
3.11.5	Management	169
3.11.6	Prognosis	170
3.12	Pandemic Diagnostics.....	171
3.12.1	Risk Management – Spark and Spread	171
3.12.2	Dx Technology – Nucleic Acid Based.....	173
3.12.3	Dx Technology - Immunoassay & Serology	174

3.12.4	Time to Market and Preparedness Issues	175
3.12.5	Unrecognized Role of Multiplex in Pandemic Mangement.....	175
4	Industry Overview.....	177
4.1	Players in a Dynamic Market.....	178
4.1.1	Academic Research Lab	179
4.1.2	Diagnostic Test Developer.....	180
4.1.3	Instrumentation Supplier	180
4.1.4	Chemical/Reagent Supplier.....	180
4.1.5	Pathology Supplier	181
4.1.6	Independent Clinical Laboratory	181
4.1.7	Public National/regional Laboratory	181
4.1.8	Hospital Laboratory	182
4.1.9	Physicians Office Lab (POLs)	182
4.1.10	Audit Body	183
4.1.11	Certification Body.....	183
4.2	The Clinical Laboratory Market Segments	185
4.2.1	Traditional Market Segmentation.....	185
4.2.2	Laboratory Focus and Segmentation.....	187
4.3	Industry Structure.....	189
4.3.1	Hospital Testing Share	189
4.3.2	Economies of Scale.....	189
4.3.2.1	Hospital vs. Central Lab.....	190
4.3.3	Physician Office Lab's.....	191
4.3.4	Physician's and POCT	191

5	Profiles of Key MDx Companies	193
5.1	1928 Diagnostics.....	194
5.2	Abacus Diagnostica	195
5.3	Abbott Laboratories.....	196
5.4	Accelerate Diagnostics	198
5.5	Access Bio.....	199
5.6	Ador Diagnostics	200
5.7	ADT Biotech	201
5.8	Akonni Biosystems	202
5.9	Altona Diagnostics	203
5.10	Alveo Technologies.....	204
5.11	Anatolia Geneworks	205
5.12	Anitoo.....	206
5.13	Antelope Dx.....	207
5.14	Applied BioCode.....	208
5.15	Assurance Scientific Laboratories	210
5.16	Aureum Diagnostics	211
5.17	Aus Diagnostics	212
5.18	Beckman Coulter Diagnostics.....	213
5.19	Becton, Dickinson and Company	214
5.20	Binx Health	216
5.21	Biocartis.....	218
5.22	BioFire Diagnostics (bioMérieux)	219
5.23	bioMérieux Diagnostics.....	221

5.24	Bio-Rad Laboratories, Inc.....	224
5.25	Bosch Healthcare Solutions GmbH.....	226
5.26	Celemics.....	227
5.27	Cepheid (Danaher).....	228
5.28	Chembio.....	230
5.29	Co Diagnostics.....	231
5.30	Credo Diagnostics Biomedical.....	232
5.31	Cue Health.....	233
5.32	Curetis N.V. / Curetis GmbH.....	235
5.33	Detect.....	236
5.34	Diagenode Diagnostics.....	237
5.35	Diascopic.....	238
5.36	Diasorin S.p.A.....	239
5.37	Domus Diagnostics.....	241
5.38	Eiken Chemical.....	242
5.39	Element Biosciences.....	243
5.40	Enzo Biochem.....	244
5.41	Eurofins Scientific.....	246
5.42	Fluxergy.....	248
5.43	Fulgent Genetics.....	249
5.44	Fusion Genomics.....	250
5.45	Genedrive.....	252
5.46	Genetic Signatures.....	253
5.47	GenMark Dx (Roche).....	254

5.48	Genomadix.....	256
5.49	Grifols.....	257
5.50	Grip Molecular Technologies	258
5.51	Hibergene Diagnostics.....	259
5.52	Hologic	260
5.53	Illumina	262
5.54	Immunexpress.....	263
5.55	Inflammatix	264
5.56	Invetech.....	265
5.57	Janssen Diagnostics	266
5.58	Karius	267
5.59	Lexagene	269
5.60	LightDeck Diagnostics	270
5.61	Lucira Health.....	271
5.62	Luminex Corp (DiaSorin)	272
5.63	LumiraDx	274
5.64	Lumos Diagnostics.....	275
5.65	Mammoth Biosciences	276
5.66	Maxim Biomedical	277
5.67	Meridian Bioscience.....	278
5.68	Mesa Biotech (Thermo Fisher)	280
5.69	MicroGem.....	281
5.70	Millipore Sigma	282
5.71	Mindray	283

5.72	Minute Molecular	284
5.73	Mobidiag (Hologic)	285
5.74	Molbio Diagnostics	286
5.75	NanoDx	287
5.76	Nanomix	288
5.77	Novacyt	289
5.78	Novel Microdevices	290
5.79	OnsiteGene	291
5.80	Operon	292
5.81	Oxford Nanopore Technologies	293
5.82	Panagene	294
5.83	Pathogenomix	295
5.84	Perkin Elmer	296
5.85	Prenetics	298
5.86	Primerdesign (Novacyt)	299
5.87	Prominex	300
5.88	Proof Diagnostics	302
5.89	Qiagen	303
5.90	QuantuMDx	305
5.91	Quest Diagnostics	306
5.92	QuidelOrtho	307
5.93	Randox Toxicology	309
5.94	Roche Molecular Diagnostics	310
5.95	Saw Diagnostics	312

5.96	Scope Fluidics	313
5.97	SD Biosensor	314
5.98	Seegene.....	316
5.99	Siemens Healthineers	318
5.100	Singular Genomics	319
5.101	SomaLogic	321
5.102	Sona Nanotech	322
5.103	SpeedX.....	323
5.104	T2 Biosystems.....	324
5.105	Talis Biomedical	325
5.106	Thermo Fisher Scientific Inc.....	326
5.107	Ultima Genomics	329
5.108	Vela Diagnostics.....	330
5.109	Veramarx	331
5.110	Veredus Laboratories.....	332
5.111	Vir.....	333
5.112	Vircell.....	334
5.113	Visby Medical	335
5.114	XCR Diagnostics	337
5.115	YD Diagnostics.....	338
5.116	Zhejiang Orient Gene Biotech	340
6	Market Trends	342
6.1	Factors Driving Growth	343
6.1.1	New Genotypes Creating New Markets	344

6.1.2	The Aging Effect	344
6.1.3	Developing World Driving ID Dx Growth.....	346
6.1.4	Point of Care – Why Centralization is Losing Steam	346
6.1.5	Self Testing.....	347
6.1.6	The Need for Speed	347
6.1.7	The COVID Pandemic.....	347
6.2	Factors Limiting Growth	349
6.2.1	Lower Costs.....	349
6.2.2	Infectious Disease is Declining.....	351
6.2.3	Wellness Hurts.....	351
6.2.4	Economic Growth improves Living Standards	351
6.3	Instrumentation and Automation	352
6.3.1	Instruments Key to Market Share.....	352
6.3.2	The Shrinking Machine	352
6.3.3	Multiplex, Point of Care and The Speed Factor.....	352
6.4	Diagnostic Technology Development	354
6.4.1	The Sepsis Testing Market – A New Direction?	355
6.4.2	POCT/Self Testing as a Disruptive Force	355
6.4.3	The Genetics Play – One Test for All Known Infections.....	356
6.4.4	Antibiotic Resistance Genes – Simplifying Diagnostics.....	356
7	Molecular Dx – Infectious Disease Recent Developments	357
7.1	Recent Developments – Importance and How to Use This Section	358
7.1.1	Importance of These Developments	358
7.1.2	How to Use This Section.....	358

7.2	Binx Health Refocuses on POC STD Testing	358
7.3	LetsGetChecked Authorized for STD Test.....	361
7.4	Genetic Signatures Applies for GI Parasite Detection Kit	362
7.5	Sensible Diagnostics Nabs Award for Respiratory Panel.....	363
7.6	Post-Pandemic Changes Landscape of ID Dx	363
7.7	Multiplex Meningitis/Encephalitis Panel Market Expanding	377
7.8	Sensible Diagnostics to Launch 10-Minute POC PCR System.....	387
7.9	ReadyGo Dx Emerges From Stealth With MDx Plan	390
7.10	BioMérieux, Oxford Nanopore Form ID Dx Pact	395
7.11	SD Biosensor Eyes Global Expansion for Rapid MDx System	399
7.12	Compact POCT Platform Unlocks Multiplexing Potential of Real-Time PCR	405
7.13	Takara Bio and BioExcel Partner on ID Panels.....	406
7.14	BioGX introduces pixl real-time PCR platform.....	407
7.15	Sherlock Biosciences Improves ID Dx Toolkit	408
7.16	Climate change is making hundreds of diseases much worse.....	412
7.17	BioMérieux Invests in Sepsis Dx Startup Weezion.....	414
7.18	Domus Diagnostics to Launch POC MDx Test System.....	415
7.19	Proof Dx Plans Infectious Disease, Oncology Tests for CRISPR-Based POC	418
7.20	Oxford Nanopore Diagnostics to Develop Clinical Tools.....	421
7.21	Pathogenomix Developing Infectious Disease Platform Using NGS	424
7.22	COVID-19 Accelerating Trend Toward Pharmacy-Based Testing	429
7.23	Co-Diagnostics Seeks FDA EUA for At-Home PCR Diagnostic	432
7.24	Sense Biodetection to Debut Instrument-Free Point-of-Care MDx.....	436
7.25	Home Test Company Prenetics to go Public	440

7.26	Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio.....	442
7.27	Lucira Health Posts Revenue Growth on OTC C19 Test	442
7.28	BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform	443
7.29	Talis Biomedical Discusses Point-of-Care	447
7.30	Roche to Acquire GenMark Diagnostics for \$1.8B	451
7.31	Pandemic Pushes Handheld qPCR Devices Closer to Commercialization.....	452
7.32	Hologic to Acquire Mobidiag	460
7.33	Lucira Health Focuses on User Friendly Approach to Home Testing	461
7.34	Infectious Disease Dx Firm Talis Biomedical Raises \$254M in IPO.....	467
7.35	Fluidigm Plans 'Durable' Diagnostics, Clinical Business.....	467
7.36	Thermo Fisher Scientific to Acquire Mesa Biotech for Up to \$550M	471
7.37	Mammoth Biosciences Developing Pathogen Detection Tech	472
7.38	Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests	475
7.39	Scanogen Developing 90 Minute Infection Test.....	480
7.40	Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection	483
7.41	FDA Provides Self Testing SARS-CoV-2 EAU Guidance	486
7.42	Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic	488
7.43	Genetic Signatures Gets CE Mark for Coronavirus Molecular Test	489
7.44	Qiagen Respiratory Panel with Coronavirus Receives CE Mark.....	490
7.45	Lumos Diagnostics Closes \$15M Series A Funding	491
7.46	Fusion Genomics to Assess NGS-Based Respiratory Tract Infection Assay	492
8	The Global Market for Molecular Diagnostics Infectious Disease	494
8.1	Global Market Overview by Country	495
8.1.1	Table – Global Market by Country.....	495

8.1.2	Chart - Global Market by Country	496
8.2	Global Market by Syndrome - Overview	497
8.2.1	Table – Global Market by Syndrome	497
8.2.2	Chart – Global Market by Syndrome – Base/Final Year Comparison	498
8.2.3	Chart – Global Market by Syndrome – Base Year	499
8.2.4	Chart – Global Market by Syndrome – End Year	500
8.2.5	Chart – Global Market by Syndrome – Share by Year	501
8.2.6	Chart – Global Market by Syndrome – Segments Growth.....	502
8.3	Global Market by Plex - Overview	503
8.3.1	Table – Global Market by Plex.....	503
8.3.2	Chart – Global Market by Plex – Base/Final Year Comparison	504
8.3.3	Chart – Global Market by Plex – Base Year.....	505
8.3.4	Chart – Global Market by Plex – End Year	506
8.3.5	Chart – Global Market by Plex – Share by Year.....	507
8.3.6	Chart – Global Market by Plex – Segments Growth	508
8.4	Global Market by Place - Overview	509
8.4.1	Table – Global Market by Place.....	509
8.4.2	Chart – Global Market by Place – Base/Final Year Comparison	510
8.4.3	Chart – Global Market by Place – Base Year.....	511
8.4.4	Chart – Global Market by Place – End Year	512
8.4.5	Chart – Global Market by Place – Share by Year.....	513
8.4.6	Chart – Global Market by Place – Segments Growth.....	514
9	Global MDx Infectious Disease Markets – By Syndrome	515
9.1	Respiratory	516

9.1.1	Table Respiratory – by Country	516
9.1.2	Chart - Respiratory Growth.....	517
9.2	Gastrointestinal.....	518
9.2.1	Table Gastrointestinal – by Country	518
9.2.2	Chart - Gastrointestinal Growth	519
9.3	Blood	520
9.3.1	Table Blood – by Country	520
9.3.2	Chart - Blood Growth.....	521
9.4	Meningitis/Encephalitis	522
9.4.1	Table Meningitis/Encephalitis – by Country.....	522
9.4.2	Chart - Meningitis/Encephalitis Growth	523
9.5	Sexually Transmitted Disease.....	524
9.5.1	Table Sexually Transmitted Disease – by Country	524
9.5.2	Chart – Sexually Transmitted Disease Growth.....	525
9.6	Other	526
9.6.1	Table Other – by Country	526
9.6.2	Chart - Other Growth.....	527
10	Global MDx Markets for Infectious Disease – by Plex.....	528
10.1	Single Plex	529
10.1.1	Table Single Plex – by Country.....	529
10.1.2	Chart - Single Plex Growth.....	530
10.2	Duplex	531
10.2.1	Table Duplex – by Country	531
10.2.2	Chart - Duplex Growth.....	532

10.3	Triplex.....	533
10.3.1	Table Triplex – by Country.....	533
10.3.2	Chart - Triplex Growth.....	534
10.4	Multiplex Technology.....	535
10.4.1	Table Multiplex – by Country.....	535
10.4.2	Chart - Multiplex Growth.....	536
11	Global MDx Infectious Disease Markets – by Place.....	537
11.1	Hospital Lab.....	538
11.1.1	Table Hospital Lab – by Country.....	538
11.1.2	Chart - Hospital Lab Growth.....	539
11.2	Outpatient Lab.....	540
11.2.1	Table Outpatient Lab – by Country.....	540
11.2.2	Chart - Outpatient Lab Growth.....	541
11.3	POC.....	542
11.3.1	Table POC – by Country.....	542
11.3.2	Chart - POC Growth.....	543
11.4	Other Place.....	544
11.4.1	Table Other Place– by Country.....	544
11.4.2	Chart – Other Place Growth.....	545
12	Appendices.....	546
12.1	United States Medicare System: Clinical Laboratory Fees Schedule.....	547
12.2	The Most Used IVD Assays.....	658
12.3	The Highest Grossing Assays.....	663

Table of Tables

Table 1 Classification of HIV Species.....	47
Table 2 HIV Tests - CMS Codes & Prices	70
Table 3 Current HIV Molecular Tests and Instruments Used.....	71
Table 4 HBV Tests - CMS Codes & Prices.....	82
Table 5 HCV Tests - CMS Codes & Prices	90
Table 6 HPV Clearance Rates	96
Table 7 HPV Tests - CMS Codes & Prices.....	101
Table 8 HPV Tests, Technology, Types	102
Table 9 Types of Influenza Tests	114
Table 10 Influenza Tests - CMS Codes & Prices.....	117
Table 11 FDA Cleared Molecular Assays for Influenza	118
Table 12 FDA Cleared NAAT CTGC Tests	132
Table 13 CTGC NAAT Target Sequences and Possible False Reactions	136
Table 14 CTGC Tests - CMS Codes & Prices.....	141
Table 15 FDA Approved MDx Tests for Tuberculosis.....	148
Table 16 Tuberculosis Tests - CMS Codes & Prices.....	149
Table 17 FDA Approved Tests for MRSA	152
Table 18 MRSA Tests - CMS Codes & Prices	154
Table 19 FDA Approved Tests for VRE	156
Table 20 VRE Tests - CMS Codes & Prices	157

Table 21 FDA Approved Multiplex Assays.....	159
Table 22 Characteristics of Coronavirus Pandemic Infections	162
Table 23 COVID-19 Symptoms.....	164
Table 24 Market Players by Type	179
Table 25 Clinical Laboratory Departments and Segments	186
Table 26 Laboratory Management Focus – Different Approaches	187
Table 27 Key Segmentation Variables Going Forward.....	188
Table 28 Five Factors Driving Growth	343
Table 29 Four Factors Limiting Growth	349
Table 30 Key Diagnostic Laboratory Technology Trends	354
Table 31 - Global Market by Region	495
Table 32 Global Market by Syndrome	497
Table 33 Global Market by Plex.....	503
Table 34 Global Market by Place.....	509
Table 35 Respiratory by Country.....	516
Table 36 Gastrointestinal by Country	518
Table 37 Blood by Country.....	520
Table 38 Meningitis/Encephalitis by Country.....	522
Table 39 Sexually Transmitted Disease by Country	524
Table 40 Other by Country.....	526
Table 41 Single Plex by Country.....	529
Table 42 Duplex by Country	531
Table 43 Triplex by Country	533
Table 44 Multiplex by Country	535

Table 45 Hospital Lab by Country 538

Table 46 Outpatient Lab by Country 540

Table 47 POC by Country 542

Table 48 Other Place by Country 544

Table 49 Clinical Lab Fee Schedule 547

Table 50 The Most Common Assays 658

Table 51 Largest Revenue Assays 663

Table of Figures

Figure 1 Global Healthcare Spending	42
Figure 2 The Lab Test Pie	43
Figure 3 HIV Virion	48
Figure 4 Diagram of the HIV Replication Cycle	52
Figure 5 The Structure of the HBV Virus.....	76
Figure 6 Hepatitis B Replication	77
Figure 7 Structure of the HCV Virus.....	84
Figure 8 HCV Replication Cycle	87
Figure 9 Structure of the Influenza Virion	110
Figure 10 Influenza Replication.....	111
Figure 11 Scanning Electronmicrograph of Tuberculosis.....	144
Figure 12 The Road to Diagnostics	178
Figure 13 The Changing Age of The World's Population.....	345
Figure 14 Health Care Consumption by Age	345
Figure 15 Cancer Incidence by Age	346
Figure 16 Chart Infectious Disease Decline	350
Figure 17 Global Market Shares Chart.....	496
Figure 18 Global Market by Syndrome - Base vs. Final	498
Figure 19 Global Market by Syndrome Base Year	499
Figure 20 Global Market by Syndrome End Year	500
Figure 21 Syndrome Share by Year	501

Figure 22 Syndrome Segments Growth.....	502
Figure 23 Global Market by Plex - Base vs. Final.....	504
Figure 24 Global Market by Plex Base Year.....	505
Figure 25 Global Market by Plex End Year	506
Figure 26 Plex Share by Year.....	507
Figure 27 Plex Segments Growth.....	508
Figure 28 Global Market by Place - Base vs. Final.....	510
Figure 29 Global Market by Place Base Year.....	511
Figure 30 Global Market by Place End Year	512
Figure 31 Place Share by Year.....	513
Figure 32 Place Segments Growth.....	514
Figure 33 Respiratory Growth.....	517
Figure 34 Gastrointestinal Diagnostics Growth.....	519
Figure 35 Blood Growth.....	521
Figure 36 Meningitis/Encephalitis Growth.....	523
Figure 37 Sexually Transmitted Disease Growth	525
Figure 38 Other Growth.....	527
Figure 39 Single Plex Growth.....	530
Figure 40 Duplex Growth.....	532
Figure 41 Triplex Growth	534
Figure 42 Multiplex Growth	536
Figure 43 Hospital Lab Growth.....	539
Figure 44 Outpatient Lab Growth	541
Figure 45 POC Growth.....	543

Figure 46 Other Place Growth 545